-
Site License
-
Site License
-
Enterprisewide
-
Enterprisewide
Opportunities for Bioinformatics in European Drug Discovery Market
Frost & Sullivan, March 2005
Dwindling Drug Pipelines Strengthen Demand for Tools to Improve Productivity
Pharmaceutical companies are under immense pressure to increase their drug research productivity owing to declining drug pipelines, a lack of recent blockbuster drugs and currently available blockbuster drugs going off patent. Moreover, a large number of drug candidates fail to make it to the final approval phase. As a result, drug discovery companies are compelled to incorporate tools that can improve their productivity and reduce R&D expenditure. Bioinformatics can aid companies in reducing the time involved in drug discovery. As drug discovery companies actively pursue these tools, the bioinformatics market is anticipated to be one of the most exciting segments in the total drug discovery market.
This Frost & Sullivan research offers a comprehensive analysis of the opportunities for bioinformatics in European drug discovery market. The market is subdivided into the following categories - genomics software, proteomics software and information manipulation tools. In addition to detailed insights into market drivers and industry challenges, this study provides strategic growth recommendations.
Pressing Need for Tools to Handle the Colossal Amounts of Research Data
Drug discovery companies are facing a research data overload touching peta bytes (quadrillion bytes). As genomic and proteomic research activities worldwide generate huge amounts of data, scientists find it impossible to actually collect and analyse the data. This threatens to slow down the productivity of drug discovery companies and is the prime force behind the development of bioinformatics tools.
Moreover, bioinformatics can bring together disparate data, which is vital to a variety of research purposes. Varying range of data sets is generated during drug research and the value of a stand-alone data set, such as a bacterial genome, is negligible, notes the analyst of this research. However, the value of a sequenced genome is magnified greatly if other genomes are brought into the same conceptual space for comparison. Thus, scientists’ demand for tools to handle the information overload and the need to integrate data is likely to drive the bioinformatics market.
Growing R&D Investment by European Governments Propels the Market
European governments’ initiative to promote the merits of bioinformatics and an increase in their R&D investments are set to positively influence the market. Greater research efforts by the government along with the adoption of bioinformatics tools by a large number of drug discovery companies to improve their productivity promise substantial growth opportunities for bioinformatics in the European drug discovery market, concludes the analyst.
1. Executive Summary
- 1. Executive Summary
- - 1. Executive Summary
2. Exchange Rates and Glossary of Terms
- 1. Exchange Rates and Glossary of Terms
- - 1. Exchange Rates
- - 2. Glossary of Terms
3. Industry Challenges
- 1. Introduction
- - 1. Introduction
- 2. Industry Challenges and Issues
- - 1. Industry Challenges and Issues
4. Market Engineering Research for the Bioinformatics Market in Europe
- 1. Forecasts for the Total European Bioinformatics Market
- - 1. Market Overview
- - 2. Market Segmentation
- - 3. Market Engineering Measurements
- - 4. Market Drivers
- - 5. Market Restraints
- - 6. Revenue Forecasts
- - 7. Geographical Trends
- - 8. Technology Trends and their Impacts
- - 9. End-user Trends
- - 10. Competitive Structure
- 2. European Bioinformatics Market: Genomics Market Segment
- - 1. Introduction to Genomics and Its Technologies
- - 2. Market Overview
- - 3. Market Engineering Measurements
- - 4. Industry Challenges
- - 5. Revenue Forecasts
- - 6. Competitive Structure
- 3. European Bioinformatics Market: Proteomics Market Segment
- - 1. Introduction to Proteomics and Its Technologies
- - 2. Market Overview
- - 3. Market Engineering Measurements
- - 4. Industry Challenges
- - 5. Revenue Forecasts
- - 6. Competitive Structure
- 4. European Bioinformatics Market: Information Manipulation Segment
- - 1. Market Overview
- - 2. Market Engineering Measurements
- - 3. Industry Challenges
- - 4. Revenue Forecasts
- - 5. Competitive Structure
5. Market Engineering Measurement for the United Kingdom Bioinformatics Market
- 1. Forecasts for the United Kingdom Bioinformatics Market
- - 1. The United Kingdom Bioinformatics Market
- - 2. Market Engineering Measurements
- - 3. Revenue Forecasts
6. Market Engineering Research for the German Bioinformatics Market
- 1. Forecast for the German Bioinformatics Market
- - 1. German Bioinformatics Market
- - 2. Market Engineering Measurements
- - 3. Revenue Forecasts
7. Market Engineering Research for the French Bionformatics Market
- 1. Forecasts for the French Bioinformatics Market
- - 1. French Bioinformatics Market
- - 2. Market Engineering Measurements
- - 3. Revenue Forecasts
8. Market Engineering Research for the Scandinavian Bioinformatics Market
- 1. Forecasts for the Scandinavian Bioinformatics Market
- - 1. Scandinavian Bioinformatics Market
- - 2. Market Engineering Measurements
- - 3. Revenue Forecasts
9. Market Engineering Research for the Benelux Bioinformatics Market
- 1. Revenue Forecasts for the Benelux Bioinformatics Market
- - 1. Benelux Bioinformatics Market
- - 2. Market Engineering Measurements
- - 3. Revenue Forecasts
10. Market Engineering Strategic Recommendations
- 1. Strategic Recommendations
- - 1. Market Engineering Research Strategic Recommendations
11. Frost & Sullivan Awards for the European Bioinformatics Market
- 1. Awards for European Bioinformatics Market
- - 1. Frost & Sullivan Awards for European Bioinformatics Market
- - 2. Business Development Strategy Leadership Award
- - 3. Entrepreneurial Company Award
- - 4. Product Innovation Award
- - 5. Technology Leadership Award
12. Database of Key Industry Participants
- 1. Database of Key Industry Participants
- - 1. Database of Key Industry Participants
13. Decision Support Databases
- 1. Biotech Companies and Number of Employees
- - 1. Number of Biotech Companies
- - 2. Number of Employees in Biotech Companies
- 2. Government R&D Expenditure
- - 1. Government R&D Expenditure
- 3. Private Investment in Biotechnology
- - 1. Private Investment in Biotechnology
- 4. Pharma R&D Expenditure
- - 1. Pharmaceutical R&D Expenditure
Customers who bought this item also bought
All rights reserved. © Copyright 2013 Research and Markets WWW5
Terms and Conditions Privacy Policy Publishers Employment Opportunities Site Map Link to us Webmaster Affiliate Network
